Mikami M, Aoki Y, Sakamoto M, Shimada M, Takeshima N, Fujiwara H, et al. Current surgical principle for uterine cervical cancer of stages Ia2, Ib1, and IIa1 in Japan: a survey of the Japanese Gynecologic Oncology Group. Int J Gynecol Cancer. 2013;23(9):1655–60. quiz 1661–1652.
Article
PubMed
Google Scholar
X. Xia, H. Xu, Z. Wang, R. Liu, T. Hu, S. Li: Analysis of Prognostic Factors Affecting the Outcome of Stage IB-IIB Cervical Cancer Treated by Radical Hysterectomy and Pelvic Lymphadenectomy. Am J Clin Oncol. 2014. epub ahead of print.
Ferrandina G, Ercoli A, Fagotti A, Fanfani F, Gallotta V, Margariti AP, et al. Completion surgery after comcomitant chemoradiation in locally advanced cervical cancer: a comprehensive analysis of pattern of postoperative complications. Ann Surg Oncol. 2014;21(5):1692–9.
Article
PubMed
Google Scholar
Kim HS, Sardi JE, Katsumata N, Ryu HS, Nam JH, Chung HH, et al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis. Eur J Surg Oncol. 2013;39(2):115–24.
Article
CAS
PubMed
Google Scholar
Balko JM, Black EP. Ovarian carcinoma as a surrogate tumor for lung adenocarcinomas in evaluating the chemo-stability of a gene expression signature. Cancer Biol Ther. 2009;8(2):167–73.
Article
CAS
PubMed
Google Scholar
Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 2001;61(24):8654–8.
CAS
PubMed
Google Scholar
Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108–12.
Article
CAS
PubMed
PubMed Central
Google Scholar
Abazeed ME, Adams DJ, Hurov KE, Tamayo P, Creighton CJ, Sonkin D, et al. Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res. 2013;73(20):6289–98.
Article
CAS
PubMed
Google Scholar
Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics. 2007;17(7):497–504.
Article
CAS
PubMed
Google Scholar
Yamaguchi S, Nishimura R, Yaegashi N, Kiguchi K, Sugiyama T, Kita T, et al. Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065). Oncol Rep. 2012;28(2):487–93.
CAS
PubMed
Google Scholar
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
Article
CAS
PubMed
Google Scholar
Fujii S, Takakura K, Matsumura N, Higuchi T, Yura S, Mandai M, et al. Anatomic identification and functional outcomes of the nerve sparing Okabayashi radical hysterectomy. Gynecol Oncol. 2007;107(1):4–13.
Article
PubMed
Google Scholar
Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–81.
Article
PubMed
Google Scholar
Broberg P. Statistical methods for ranking differentially expressed genes. Genome Biol. 2003;4(6):R41.
Article
PubMed
PubMed Central
Google Scholar
Choe SE, Boutros M, Michelson AM, Church GM, Halfon MS. Preferred analysis methods for Affymetrix GeneChips revealed by a wholly defined control dataset. Genome Biol. 2005;6(2):R16.
Article
PubMed
PubMed Central
Google Scholar
Fukui T, Mitsufuji H, Kubota M, Inaoka H, Hirose M, Iwabuchi K, et al. Prevalence of topoisomerase I genetic mutations and UGT1A1 polymorphisms associated with irinotecan in individuals of Asian descent. Oncol Lett. 2011;2(5):923–8.
CAS
PubMed
PubMed Central
Google Scholar
Rosa DD, Medeiros LR, Edelweiss MI, Pohlmann PR, Stein AT. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev. 2012;6:CD005342.
PubMed
PubMed Central
Google Scholar
Xiang EW, Shu-mo C, Ya-qin D, Ke W. Treatment of late recurrent vaginal malignancy after initial radiotherapy for carcinoma of the cervix: an analysis of 73 cases. Gynecol Oncol. 1998;69(2):125–9.
Article
Google Scholar
Chen H, Liang C, Zhang L, Huang S, Wu X. Clinical efficacy of modified preoperative neoadjuvant chemotherapy in the treatment of locally advanced (stage Ib2 to IIb) cervical cancer: A randomized study. Gynecol Oncol. 2008;110(3):308–15.
Article
CAS
PubMed
Google Scholar
Raspagliesi F, Ditto A, Selvaggi L, Frigerio L, Melpignano M, Scambia G, et al. A phase 2 multicenter study of irinotecan and cisplatinum as neoadjuvant treatment in patients with locally advanced cervical cancer, International journal of gynecological cancer. Int J Gynecol Cancer. 2010;20(9):1569–75.
PubMed
Google Scholar
Mousavia AS, Vahidi S, Karimi-Zarchi M, Modarress-Gilania M, Ghaemmaghamia F. Response to neoadjuvant chemotherapy with paclitaxel and cisplatin in locally advanced cervical cancer. Eur J Gynaecol Oncol. 2013;34(6):527–31.
CAS
PubMed
Google Scholar
Zanaboni F, Grijuela B, Giudici S, Cormio G, Babilonti L, Ghezzi F, et al. Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric study. Eur J Cancer. 2013;49(5):1065–72.
Article
CAS
PubMed
Google Scholar
Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603–7.
Article
CAS
PubMed
PubMed Central
Google Scholar
Chintala S, Toth K, Yin MB, Bhattacharya A, Smith SB, Ola MS, et al. Downregulation of cystine transporter xc by irinotecan in human head and neck cancer FaDu xenografts. Chemotherapy. 2010;56(3):223–33.
Article
CAS
PubMed
PubMed Central
Google Scholar
Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D’Andrea M, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer, Journal of clinical oncology. J Clin Oncol. 2006;24(19):3061–8.
Article
CAS
PubMed
Google Scholar
Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, Ueyama Y, et al. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res. 2002;62(2):518–27.
CAS
PubMed
Google Scholar
Cummings J, Ethell BT, Jardine L, Boyd G, Macpherson JS, Burchell B, et al. Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Res. 2003;63(23):8443–50.
CAS
PubMed
Google Scholar